help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Related articles in The Oncologist
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rothenberg, M. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rothenberg, M. L.
The Oncologist, Vol. 6, No. 1, 66-80, February 2001
© 2001 AlphaMed Press

PROMISING NEW DRUGS AND COMBINATIONS

Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond

Mace L. Rothenberg

Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USA

Correspondence: Correspondence: Mace L. Rothenberg, M.D., Division of Hematology/Oncology, Vanderbilt University Medical Center, 1956 The Vanderbilt Clinic, Nashville, TN 37232-5536, USA. Telephone: 615-322-4967; Fax: 615-343-7602; e-mail: mace.rothenberg{at}mcmail.vanderbilt.edu

Since its approval in the United States in 1996, irinotecan (CPT-11, Camptosar®, Pharmacia Corp.; Peapack, NJ) has undergone extensive clinical evaluation. In the past five years, the focus of development has evolved from evaluation of single-agent activity in refractory disease settings to evaluation of front-line irinotecan-based combination chemotherapy regimens and integration of irinotecan into combined modality regimens. Important studies have been performed clarifying the role of irinotecan in treating colorectal and other gastrointestinal cancers, small cell and non-small cell lung cancer, and a variety of other malignancies. Preclinical studies performed in conjunction with these clinical trials have also provided significant insights into the pharmacology, metabolism, mechanisms of resistance, and molecular determinants of response. This review summarizes that progress, focusing on the achievements of the past five years.

Key Words. Irinotecan • Colorectal cancer • CPT-11 • Topoisomerase • Review


Related articles in The Oncologist:

Irinotecan: A New Agent Comes of Age
Leonard B. Saltz
The Oncologist 2001 6: 65. [Full Text]  

Irinotecan Plus Fluorouracil/Leucovorin for Metastatic Colorectal Cancer: A New Survival Standard
Leonard B. Saltz, Jean-Yves Douillard, Nicoletta Pirotta, May Alakl, Gabriela Gruia, Lucile Awad, Gary L. Elfring, Paula K. Locker, and Langdon L. Miller
The Oncologist 2001 6: 81-91. [Abstract] [Full Text]  



This article has been cited by other articles:


Home page
 J. Nutr.Home page
H. Xue, M. B. Sawyer, C. J. Field, L. A. Dieleman, D. Murray, and V. E. Baracos
Bolus Oral Glutamine Protects Rats against CPT-11-Induced Diarrhea and Differentially Activates Cytoprotective Mechanisms in Host Intestine but Not Tumor
J. Nutr., April 1, 2008; 138(4): 740 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Xue, M. B. Sawyer, C. J. Field, L. A. Dieleman, and V. E. Baracos
Nutritional Modulation of Antitumor Efficacy and Diarrhea Toxicity Related to Irinotecan Chemotherapy in Rats Bearing the Ward Colon Tumor
Clin. Cancer Res., December 1, 2007; 13(23): 7146 - 7154.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. N. Tallman, J. K. Ritter, and P. C. Smith
DIFFERENTIAL RATES OF GLUCURONIDATION FOR 7-ETHYL-10-HYDROXY-CAMPTOTHECIN (SN-38) LACTONE AND CARBOXYLATE IN HUMAN AND RAT MICROSOMES AND RECOMBINANT UDP-GLUCURONOSYLTRANSFERASE ISOFORMS
Drug Metab. Dispos., July 1, 2005; 33(7): 977 - 983.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G. L. Scheffer, P. Wielinga, S. L. Cohn, W. B. London, G. M. Marshall, et al.
Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro
Mol. Cancer Ther., April 1, 2005; 4(4): 547 - 553.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
L. Paoluzzi, A. S. Singh, D. K. Price, R. Danesi, R. H. J. Mathijssen, J. Verweij, W. D. Figg, and A. Sparreboom
Influence of Genetic Variants in UGT1A1 and UGT1A9 on the In Vivo Glucuronidation of SN-38
J. Clin. Pharmacol., August 1, 2004; 44(8): 854 - 860.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
S. P. Sanghani, S. K. Quinney, T. B. Fredenburg, W. I. Davis, D. J. Murry, and W. F. Bosron
HYDROLYSIS OF IRINOTECAN AND ITS OXIDATIVE METABOLITES, 7-ETHYL-10-[4-N-(5-AMINOPENTANOIC ACID)-1-PIPERIDINO] CARBONYLOXYCAMPTOTHECIN AND 7-ETHYL-10-[4-(1-PIPERIDINO)-1-AMINO]-CARBONYLOXYCAMPTOTHECIN, BY HUMAN CARBOXYLESTERASES CES1A1, CES2, AND A NEWLY EXPRESSED CARBOXYLESTERASE ISOENZYME, CES3
Drug Metab. Dispos., May 1, 2004; 32(5): 505 - 511.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Cummings, B. T. Ethell, L. Jardine, G. Boyd, J. S. Macpherson, B. Burchell, J. F. Smyth, and D. I. Jodrell
Glucuronidation as a Mechanism of Intrinsic Drug Resistance in Human Colon Cancer: Reversal of Resistance by Food Additives
Cancer Res., December 1, 2003; 63(23): 8443 - 8450.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
H. Jinno, M. Saeki, Y. Saito, T. Tanaka-Kagawa, N. Hanioka, K. Sai, N. Kaniwa, M. Ando, K. Shirao, H. Minami, et al.
Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 688 - 693.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell
Antisense Bcl-xl Down-Regulation Switches the Response to Topoisomerase I Inhibition from Senescence to Apoptosis in Colorectal Cancer Cells, Enhancing Global Cytotoxicity
Clin. Cancer Res., July 1, 2003; 9(7): 2856 - 2865.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
H. Jinno, T. Tanaka-Kagawa, N. Hanioka, M. Saeki, S. Ishida, T. Nishimura, M. Ando, Y. Saito, S. Ozawa, and J.-i. Sawada
Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38), an Active Metabolite of Irinotecan (CPT-11), by Human UGT1A1 Variants, G71R, P229Q, and Y486D
Drug Metab. Dispos., January 1, 2003; 31(1): 108 - 113.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Xu and M. A. Villalona-Calero
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity
Ann. Onc., December 1, 2002; 13(12): 1841 - 1851.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Baudin, C. Docao, C. Gicquel, G. Vassal, A. Bachelot, A. Penfornis, and M. Schlumberger
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma
Ann. Onc., November 1, 2002; 13(11): 1806 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J.-F. Gagne, V. Montminy, P. Belanger, K. Journault, G. Gaucher, and C. Guillemette
Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38)
Mol. Pharmacol., September 1, 2002; 62(3): 608 - 617.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. B. Saltz
Irinotecan: A New Agent Comes of Age
Oncologist, February 1, 2001; 6(1): 65 - 65.
[Full Text]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.